GIGABYTE
3.1.2022 07:05:09 CET | Business Wire | Press release
GIGABYTE is joining CES Virtual with its website extension – INDUSTRY – to present products and solutions that propel digital transformation in industries such as 5G & telecom, automotive, creative & gaming, data centers , manufacturing, and retail.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211229005431/en/
GIGABYTE takes pride in having an incredibly deep portfolio of enterprise products that support cloud, edge, and data centers. There are over 75 servers for AMD EPYC CPU alone, as well as Intel Xeon Scalable CPU, and over 10 servers for Ampere Altra CPU, and not to forget over 20 server motherboards. GIGABYTE offers edge servers developed based on Arm architecture. These high-density Arm servers , using Ampere’s massive 80 / 128 core CPU, provide the performance, storage, network, and above all, the flexibility to be deployed for the next generation of telecommunications where processing work needs to be done on-site. GIGABYTE’s server solutions are also applicable to various industries, and are highly valued by large and small high-tech companies, medical, scientific, academic research, and public institutions, etc., and have successfully assisted them in innovation and breakthroughs in their fields.
Our industries are undergoing an invigorating metamorphosis as AI, HPC, IoT, and other breakthroughs bring about a paradigm shift. MyelinTek Inc., an investee company of GIGABYTE developed a deep learning system MLSteam, which includes optimized AI software stacking and comprehensive management tools in a user-friendly interface to make it easier for scientists to train and develop AI integration for autonomous vehicles. With the rapid development of Advanced Driver Assistance Systems (ADAS ) technology, GIGABYTE designs decision-making control units for different types of autonomous vehicles, as well as customized products such as ADAS ECUs, TCUs, assisting vehicles designers to develop their ideal products and improve the automotive industry.
GIGABYTE has years of proven experience in embedded computers and brought its latest generation of embedded systems to increase the operability of storage, logistic, and manufacturing facilities while lowering labor and management costs with the innovation of AGV, AMR, and Industrial Automation Security System. In the post-pandemic era, GIGABYTE’s embedded solutions integrated with AI and IoT technology helped automate the operation and management of open space rentals, allowing such new services to flourish.
GIGABYTE’s reputation to invent top-notch products with innovative VRM and thermal design makes the task to optimize overclocking performance on the latest Intel® Core™ CPUs easy and effective. The Z690 series motherboards provide beyond the essential features and power for both professional creators and gamers alike. Performance is the key to both immersive gameplay and smooth workflow, and GIGABYTE has taken performance above all else with this generation’s AORUS gaming laptops and the AERO creator laptops which are to be released in early 2022.
GIGABYTE has recently launched INDUSTRY to demonstrate its most pivotal products and solutions for different industries. One of the biggest highlights of the platform is its live chat function. GIGABYTE has arranged experts, who have keen insights on the industries, to standby the live chat and answer questions and inquiries made by CES visitors and buyers as they would at the physical venue. The live chat uses AI-generated avatars to show the status of its live experts, and also as a way to embrace the ‘metaverse ’ where virtual merges with reality. The INDUSTRY platform will host all products and solutions GIGABYTE is presenting at CES including trendy topics highlighted in the event and more. GIGABYTE welcomes all visitors to connect through this digital platform and see their industries from different perspectives.
INDUSTRY: https://industry.gigabyte.com
Visit GIGABYTE on CES Digital: https://gbte.tech/ces2022
View source version on businesswire.com: https://www.businesswire.com/news/home/20211229005431/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom